Stockreport

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF -- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- [Read more]